Craig Adam R
Transaction: 08/12/2026
SELL
Change
-47,436
Price
$4.44
Filing
08/13/2026
Type
SELL
X4 Pharmaceuticals, Inc.
XFOR • Biotechnology
$4.04
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$510.43M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 117.6%Manageable debt level · 0.41Healthy liquidity · 10.16Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:07 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$4.04
Change0.00%
Shares Out126.34M
Market Cap$510.43M
Enterprise Value$302.93M
52W Range2.45 - 4.83
Beta0.35
P/E-5.66
P/S32.21
P/B3.28
P/FCF-4.94
EV/Sales19.12
Price$4.04
Change0.00%
Shares Out126.34M
Market Cap$510.43M
Enterprise Value$302.93M
52W Range2.45 - 4.83
Beta0.35
P/E-5.66
P/S32.21
P/B3.28
P/FCF-4.94
EV/Sales19.12
EV/EBITDA-3.62
EV/FCF-2.93
Earnings Yield-17.66%
FCF Yield-20.24%
Dividend Yield0.00%
Gross Margin82.18%
Oper. Margin-2.47%
Profit Margin-2.26%
Debt/Eq0.41
Current Ratio10.16
Quick Ratio9.98
Target$11.67
Target Upside188.86%
Target Median$12.00
Target Range11.00 - 12.00
Volume839.09K
Avg Volume629.32K
EPS Surprise0.04
Investment DNA
How strong this company looks for long-term investors
53
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
75/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
79/100
Why this score▼
Positive revenue growth · 117.6%Manageable debt level · 0.41Healthy liquidity · 10.16Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 13 analyst votes · 2026-09-05
96/100
Bullish
Bullish
12
Hold
1
Bearish
0
Price Target
2026-08-16
Low
$11.00
Mean
$11.67
Median
$12.00
High
$12.00
Insider Transactions
Recent executive and insider activity
Volpone John
Transaction: 08/12/2026
SELL
Change
-24,576
Price
$4.44
Filing
08/13/2026
Type
SELL
Gold Kelly
Transaction: 07/01/2026
OTHER
Change
0
Price
Not reported
Filing
07/01/2026
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Craig Adam R | SELL | -47,436 | $4.44 | 08/12/2026 | 08/13/2026 |
| Volpone John | SELL | -24,576 | $4.44 | 08/12/2026 | 08/13/2026 |
| Gold Kelly | OTHER | 0 | Not reported | 07/01/2026 | 07/01/2026 |
| Gold Kelly | BUY | +110,000 | $4.08 | 07/01/2026 | 07/01/2026 |
| KIRSKE DAVID | SELL | -8,543 | $4.26 | 06/30/2026 | 07/01/2026 |
| KIRSKE DAVID | SELL | -16,961 | $4.29 | 05/12/2026 | 05/13/2026 |
| Bridger Gary | BUY | +110,000 | $4.00 | 01/01/2026 | 01/07/2026 |
| Stewart Murray | BUY | +110,000 | $4.00 | 01/01/2026 | 01/05/2026 |
| WYZGA MICHAEL S | BUY | +110,000 | $4.00 | 01/01/2026 | 01/05/2026 |
| de Craecker Francoise | BUY | +110,000 | $4.00 | 01/01/2026 | 01/05/2026 |
| KIRSKE DAVID | BUY | +1,552,769 | $1.42 | 10/29/2025 | 10/31/2025 |
| Volpone John | BUY | +2,329,154 | $1.42 | 10/29/2025 | 10/31/2025 |
| Craig Adam R | BUY | +2,329,154 | $1.42 | 10/29/2025 | 10/31/2025 |
| Craig Adam R | BUY | +86,206 | $2.90 | 10/23/2025 | 10/27/2025 |
| KIRSKE DAVID | BUY | +193,254 | Not reported | 08/14/2025 | 08/14/2025 |
| KIRSKE DAVID | BUY | +352,800 | $3.14 | 08/14/2025 | 08/14/2025 |
| Craig Adam R | BUY | +289,881 | Not reported | 08/14/2025 | 08/14/2025 |
| Craig Adam R | BUY | +529,201 | $3.14 | 08/14/2025 | 08/14/2025 |
| Volpone John | BUY | +289,881 | Not reported | 08/14/2025 | 08/14/2025 |
| Volpone John | BUY | +529,201 | $3.14 | 08/14/2025 | 08/14/2025 |